Search results: (10000)
News Cost Effectiveness of FVIII Substitution Versus Non-Factor Therapy for Hemophilia A
With new treatment options for hemophilia A without inhibitors, the question of cost-effectiveness of different treatment approaches arises. The results of a model comparing replacement therapy and emicizumab in terms of cost-effectiveness were presented at a recently held ASH conference.
News Vascular Disease in the Gradually Aging Population of Hemophiliacs: An Underestimated Problem?
The aging population of individuals with hemophilia brings new experiences and challenges, leading to the search for the safest and most effective treatments and prevention strategies for diseases typical of older age, particularly cardiovascular and cerebrovascular diseases. It is important to recognize that these complications pose a real risk for individuals with hemophilia, a risk that has thus far been somewhat underestimated.
News Position of Levodropropizine in Cough Therapy
An international group of specialists focused in 2016–2017 on a detailed evaluation of current options for cough therapy. The authors based their analysis on individually prepared reviews using Medline and Embase databases, and they presented their work's results last year in the journal Pulmonary Pharmacology & Therapeutics.
News The Brain, Too, Has Its Midlife Crisis. How Do These Changes Relate to the Risk of Dementia in Old Age?
The human brain undergoes rapid changes during certain developmental periods. Childhood, adolescence, and advanced old age undoubtedly belong to these. For much of adulthood, it seems that nothing much actually happens. However, it turns out that the brain’s clock begins to accelerate around 40–50 years of age. What impact do these gradual changes have on our future health?
News Adequate Anti-Xa Levels Are More Often Achieved in Trauma Patients When Dosing Enoxaparin Based on Weight
Thromboembolic disease (TED) is a well-known preventable cause of morbidity and mortality in trauma patients. To improve their prognosis, pharmacological thromboprophylaxis, such as with low molecular weight heparins (LMWH), is an essential part of treatment. However, previously published studies have pointed out that standard dosing of LMWH may be associated with insufficient levels of activity measured using the anti-Xa parameter.
News Benefits of Enoxaparin Prophylaxis in Pregnancy and Postpartum
Study results suggest that the use of low molecular weight heparins during pregnancy could lead to better outcomes for women with thrombophilia and recurrent miscarriages. A group of authors from Israel compared the differences in efficacy when administering two different doses of enoxaparin to women with hereditary thrombophilia and a history of two or more spontaneous miscarriages or one fetal death without obvious cause.